氟西汀卒中恢复试验FOCUS、AFFINITY和EFFECTS的统计分析计划更新
本文报告FOCUS、AFFINITY和EFFECTS三项氟西汀用于卒中恢复的大规模试验的个体患者数据荟萃分析(IPDM)的统计分析计划。将采用一阶段和二阶段IPDM方法合并数据,分析主要和次要结局及亚组效应,以提供更精确的风险获益估计。
要点
- 三项试验协作设计,共享基本方案以促进IPDM。
- IPDM将采用一阶段和二阶段方法合并数据。
- IPDM可检测比单项试验更小的总体效应并探索亚组效应。
核心结论
- 三项试验的IPDM将提供氟西汀与安慰剂风险获益的最精确估计,可靠检测更小的总体效应,并拓宽结果的普适性。
研究设计与样本
- FOCUS、AFFINITY和EFFECTS三项试验协作设计,共享基本方案,数据 secure 转移至FOCUS统计师进行一阶段和二阶段IPDM。
主要发现
- 将进行一阶段IPDM(数据合并为单一数据集,按单项试验相同分析)和二阶段IPDM(固定效应荟萃分析合并三项试验结果)。
- 将按招募国家、族裔和试验等亚组进行分析,并探索氟西汀对主要和次要结局的亚组效应。
- 将利用合并数据集研究卒中后重要问题(如癫痫、情绪低落和骨折)的预测因素。
关键数值与推荐
- IPDM的主要和次要结局域与单项试验相同。
临床怎么用
- IPDM结果可为氟西汀用于卒中恢复的风险获益提供更精确的估计,并支持亚组和普适性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three large trials of fluoxetine for stroke recovery (FOCUS (fluoxetine or control under supervision), AFFINITY (the Assessment oF FluoxetINe In sTroke recovery) and EFFECTS (Efficacy oF Fluoxetine-a randomisEd Controlled Trial in Stroke)) have been collaboratively designed with the same basic protocol to facilitate an individual patient data analysis (IPDM). The statistical analysis plan for the three individual trials has already been reported in Trials, including a brief description of the IPDM. In this protocol, we describe in detail how we will perform the IPDM. METHODS/DESIGN: Data from EFFECTS and AFFINITY will be transferred securely to the FOCUS statistician, who will perform a one-stage IPDM and a two-stage IPDM. For the one-stage IPDM, data will be combined into a single data set and the same analyses performed as described for the individual trials. For the two-stage IPDM, the results for the three individual trials will be combined using fixed effects meta-analyses. The primary and secondary outcome domains for the IPDM are the same as for individual trials. We will also perform analyses according to several subgroups including country of recruitment, ethnicity and trial. We will also explore the effects of fluoxetine on our primary and secondary outcomes in subgroups defined by combinations of characteristics. We also describe additional research questions that will be addressed using the combined data set, and published subsequently, including predictors of important post-stroke problems such as seizures, low mood and bone fractures. DISCUSSION: An IPDM of our three large trials of fluoxetine for stroke recovery will allow us to provide the most precise estimates of any risks and benefits of fluoxetine vs placebo, to detect reliably a smaller overall effect size than those detectable by the individual trials, to better determine the effects of fluoxetine vs placebo in subgroups of patients and outcomes and to broaden the generalisability of the results. Also, we may identify differences in treatment effects between studies. TRIAL REGISTRATION: FOCUS: ISRCTN ISRCTN83290762 . Registered on 23 May 2012. EudraCT 2011-005616-29 . Registered on 3 February 2012. AFFINITY: Australian New Zealand Clinical Trials Registry ACTRN12611000774921 . Registered on 22 July 2011. EFFECTS: ISRCTN ISRCTN13020412 . Registered on 19 December 2014. ClinicalTrials.gov NCT02683213 . Registered on 2 February 2016. EudraCT 2011-006130-16 . Registered on 8 August 2014.
引用
- Mead GE, Graham C, Billot L, et al. Update to the FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical analysis plan for the trials and for the individual patient data meta-analysis. Trials. 2020. PMID: 33239053. doi:10.1186/s13063-020-04875-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。